Jim Sullivan

Jim Sullivan, PhD., is a Venture Partner with Orbimed and CEO of Vanqua Bio. Prior to joining Orbimed, he was the Vice President of Research at AbbVie where he was responsible for AbbVie’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis.

Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. These include recently launched combination products for HCV (Mavyret and Viekira), the-first-in-class Bcl2 selective inhibitor, Venclexta, and multiple compounds currently in Phase II or III clinical trials. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Jim is an adjunct faculty member at Northwestern University and serves on the board of a number of companies and foundations including Regis Technologies, MATTER Healthcare Incubator, Chicago Biotechnology Accelerator, Pistoia Alliance and C2ST. He earned his bachelor’s degree and PhD. in biochemistry from Trinity College Dublin and conducted post-doctoral research in neurobiology at Northwestern University.